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Key Clinical Message
The survival of multiple myeloma patients has improved very significantly over
the last decade. Still median overall survival is inferior to 5 years. A small pro-
portion of patients survive longer than 10 years. In this paper we discuss four
cases illustrating the nonhomogeneous clinical presentation and evolution of
this subset of patients. Surprisingly, these long survivors do not always have
deep responses and some require frequent treatments, which include autologous
stem cell transplantation and novel drugs. The authors discuss several aspects
of these clinical histories, including treatment options, raising hypothesis on
their relation with long survivorship which may be important to have in con-
sideration when studying this subject.
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Introduction
Multiple myeloma (MM) is, generally, an incurable pro-
gressive neoplasm accounting for 10% of all hematologi-
cal malignancies. It was estimated in 2012 that 21,700
new cases and 10,710 deaths from the disease occurred in
the United States [1]. In the European Union, there were
~38,900 new cases and 24,300 deaths due to MM in 2012,
with only 10% of patients currently surviving longer than
10 years [2, 3]. This small but growing subset of patients
is still poorly characterized. The prevalence of this neo-
plasm, the better knowledge of MM biology, and the
availability of new treatment options set the importance
of analyzing long survivors among this group of patients.
Novel drugs used in MM include proteasome inhibitors,
and immunomodulators and newer molecules are still
under clinical development. Compared to the conventional
chemotherapeutic agents, proteasome inhibitors and im-
munomodulators have distinct, more specific mechanisms
of action. They are potent effectors, interfering directly with
the neoplastic plasma cells and the surrounding microenvi-
ronment, leading to high response rates and prolonged
overall and progression-free survival [4]. Their combina-
tion with dexamethasone or conventional chemotherapeu-
tic agents results in response rates comparable to those
produced by autologous stem cell transplantation (ASCT)
[5, 6]. Recently, the continued improvement in overall sur-
vival of MM patients treated with novel agents was con-
firmed regardless of age [7]. However, other clinical and
biological characteristics of the disease as well as patient-
and drug-dependent factors, such as treatment toxicities,
dramatically influence survival.
Well-defined molecular abnormalities are associated
with poor outcomes in MM, and gene expression profiles
and cytogenetic abnormalities can determine the patients’
prognosis [8, 9, 10, 11, 12]. Almost all MM patients har-
bor genomic abnormalities including structural and
numeric chromosomal variations, with variable complex-
ity. This is an indication of genomic instability and
intrinsic oncogenic properties and/or failure of protective
cellular mechanisms. Myeloma-initiating events such as
hyperdiploidy and chromosomal translocations leading to
activation of oncogenes, as CCND1, CCND2, c-MAF
(V-maf musculoaponeurotic fibrosarcoma oncogene
homolog), and MMSET (multiple myeloma SET domain)
are important, but not sufficient, determinants of disease
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aggressiveness. Secondary events, including activation of
oncogenes, such as RAS (RAT sarcoma) and MYC (mye-
locytomatosis viral oncogene), of NF-jB and inactivation
of tumor suppressor genes such as TP53 and RB (retino-
blastoma), are the markers of high-risk disease that char-
acterize patients with a very poor prognosis [13, 14].
Concurrent to biological disease characteristics, clinical
variables related to MM (including the ones validated in
the International Score System) advanced age and comor-
bidities also have an important negative impact. An
appropriate assessment of organ dysfunction at the begin-
ning of therapy may allow to better define treatment
strategies, improving tolerability and optimizing efficacy,
especially in the elderly [15, 16, 17].
Toxicities associated to different treatments impact in
quality of life. Neurological, hematopoietic, and cardiac
side effects are the most common toxicities in patients
under prolonged treatment. They are associated to the
broad use of alkylating agents, corticosteroids and, more
recently, proteasome inhibitors and immunomodulators.
Also, survivors of MM are confronted with nonspecific,
cancer treatment-related long-term symptoms, most com-
monly fatigue, sexual dysfunction, arthralgia, and a high
risk of second primary malignancies (SPM) [18]. High-dose
chemotherapy with autologous stem cell support became
widely used since 1990s in fit patients under 65 years of
age. Despite employing high doses of melphalan, the risk of
myelodysplastic syndromes/acute myeloid leukemia after
transplant is estimated to be less than 5%, mostly attribut-
able to pretransplant therapy [19]. Also, no significant risk
change was noted after the introduction of autologous stem
cell transplant among younger patients (<65 years) and
other novel agents [20, 21]. Recent studies have reported an
increased risk of second primary cancers following treat-
ments with immunomodulators, possibly reflecting longer
survival times. Recent published data showed that this risk
does not increase over time.
Patients with MM who are considered long survivors
are usually young patients, without high-risk cytogenetic
features and international staging score (ISS) 1, low
tumor burden (absence of severe anemia, hypercalcaemia,
renal failure, or multiple bone lesions), absence of Bence-
Jones proteinuria, low-plasma cell percentage in bone
marrow, mature and intermediate myeloma. Also, a posi-
tive response to first-line treatment and to subsequent
treatments were related to long-term survival [19, 20, 21].
Interestingly, it seems that long-term survival in MM is
associated with a distinct immunological profile, which
includes proliferative cytotoxic T-cell clones and a favor-
able Treg/Th17 balance [22].
With the aim of examining some factors that influence
long-term survivorship, we present and discuss four dif-
ferent clinical cases of long-term survivors with MM,
including both transplanted and nontransplanted patients
with a variety of comorbidities and different treatments
flows. These four patients diagnosed with MM for more
than 10 years (13, 18, 19, and 20 years) were selected
from the authors’ outpatient practice because they were
alive and are representative of the true story and hetero-
geneity of MM worldwide. The cases are summarized first
and followed by a common discussion.
Case 1
A Caucasian 56-year-old man with no relevant past medi-
cal history was diagnosed with MM IgG kappa, Durie Sal-
mon stage IIIA, ISS II in July 1996. At diagnosis, he had
a performance status (PS) of 1 and presented with a bone
marrow plasmocytosis of 65.5%, serum IgG 10,600 mg/
dL, anemia (Hb = 10.5 g/dL), and lumbar lytic lesions.
At that time no cytogenetic abnormalities were screened
by fluorescent in situ hybridization (FISH) and later (in
2011) no FISH abnormalities were detected.
First-line treatment with melphalan and prednisolone
(MP) and radiotherapy (D12-L2 – 30 Gy) were started,
but suspended after three cycles due to deep venous
thrombosis. Partial response was achieved and the patient
remained stable until 1997.
In March and May 1997, the patient underwent tandem
ASCT without further treatment, achieving a complete
response by the International Myeloma Working Group
criteria [23]. Maintenance treatment with alpha-interferon
was administered for 2 years.
Biochemical disease progression was documented in
May 2002 with positive serum immunofixation, but due
to the absence of clinical symptoms, treatment was post-
poned until December 2002, when thalidomide and pred-
nisolone were started due to bone pain and increased
serum Ig levels. After 12 cycles, thalidomide dose was
reduced to 50 mg/day due to grade 2 peripheral neuropa-
thy. The neurologic toxicity motivated the interruption of
the treatment in March 2005, despite the achievement of
very good partial response (VGPR).
Retreatment was not necessary until October 2008, when
bone pain reappeared and an increased serum Ig level was
detected. The patient was started on with lenalidomide
(monthly cycles of 25 mg/day for 21 days) and dexametha-
sone (40 mg/week). Aspirin 100 mg/day was added as
thromboprophylaxis. The patient has been kept on the
same treatment and completed 20 cycles. An ongoing com-
plete response was documented after the 11th cycle.
Case 2
A Caucasian 58-year-old woman with a medical history
of Hepatitis C, epilepsy, intestinal angiodysplasia with
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previous bleeding episodes, major depression, and a PS of
0 was diagnosed with IgG kappa MM, Durie Salmon stage
IIIA (ISS not available), in June 1994. At diagnosis, she
had 13% bone marrow infiltration by plasma cells, serum
IgG of 8731 mg/dL, and multiple painful osteolytic
lesions. At that time no cytogenetic abnormalities were
screened by FISH and in 2009 no FISH abnormalities
were detected.
First-line treatment with MP was changed to cyclo-
phosphamide and prednisolone due to no response. This
second line of treatment was maintained for four cycles
and the patient achieved stable disease. In March 1997,
she presented with bone pain, rising serum levels of
monoclonal protein and hepatomegaly, which led to the
introduction of the third line of treatment with vincris-
tine, melphalan, cyclophosphamide, and prednisone
(VMCP) alternating with vincristine, carmustine (BCNU),
doxorubicin, and prednisone (VBAP) (VMCP/VBAP).
After four cycles, a fracture in D12 with cord compres-
sion occurred. After local radiotherapy (30 Gy), she con-
tinued treatment with six cycles of infused vincristine,
adriamycin, and high-dose methylprednisolone (VAMP),
which was complicated by hematologic and infectious
toxicity, grades 2 and 3 respectively. Still, symptoms
improved and the hepatomegaly receded but by the end
of the treatment IgG had stabilized at 7200 mg/dL and
3.5% plasma cells persisted in the bone marrow.
Due to clinical stability and chemotherapy-related tox-
icities, the patient was kept without therapy for 3 years.
In 2001, she restarted VBAP (fifth line) due to biochemi-
cal progression and recurrence of pain. Partial response
was achieved after 12 cycles. In August 2002, clinical and
biochemical progression lead to treatment with thalido-
mide plus dexamethasone (sixth line) for 14 months, with
grade 2 neuropathy. However, a long-lasting partial
response was achieved and remained stable for almost
5 years. During that period, New York Heart Association
class II–III heart failure was diagnosed and attributed to
previous treatment with anthracyclins.
By the end of 2008, back pain increased and serum
monoclonal protein rose, and thalidomide and dexameth-
asone were restarted and kept until March 2010. The per-
sistence of neurological and cardiac toxicity, lead to
treatment interruption. Again, a partial response was
obtained that lasted for 24 months. In January 2012, a
new clinical relapse was treated with cyclophosphamide
and prednisolone without success. Treatment with lena-
lidomide plus dexamethasone was begun and warfarin
was used as thromboprophylaxis. The symptoms
improved and her hemoglobin values rose. She stopped
erythropoietin in January 2013. She is currently in partial
response. No major side effects were documented and no
delays in chemotherapy were needed.
Case 3
A Caucasian 32-year-old man with no relevant past
medical history and a PS of 3 due to bone pain was
diagnosed with IgG lambda MM, Durie Salmon stage
IIA, ISS I in July 1995. At diagnosis, he presented mar-
row plasmocytosis of 2.3%, serum IgG of 3238 mg/dL,
14.6 g/dL of hemoglobin, and one osseous plasmocytom-
a on the left femur that led to a pathological fracture.
At that time no cytogenetic abnormalities were screened
by FISH and in 2005 and 2012 no FISH abnormalities
were detected.
Right after diagnosis, first-line treatment with cyclo-
phosphamide and prednisone for two cycles and local
radiotherapy (RT) (40 Gy) were started, followed by vin-
cristine, doxorubicin, and dexamethasone (VAD) for six
cycles, without major toxicities. Partial response was
achieved and the patient underwent tandem ASCT in
1996 (melphalan 200 mg/m2 in conditioning for both)
with 2 years maintenance therapy with alpha-interferon.
He reached a VGPR and remained without further treat-
ment for 7 years.
In February 2005, bone pain and increasing serum M
component and bone marrow plasmocytosis were
detected. A third line of chemotherapy with cyclophos-
phamide plus dexamethasone and additional RT to con-
trol painful bone lesions was started. After four cycles
without response, a fourth line of treatment was initiated
with bortezomib and dexamethasone (VD). After eight
cycles he had had no major toxic events and achieved a
VGPR. He was proposed for a third ASCT that took place
in May 2006 (melphalan 140 mg/m2), keeping a VGPR.
The patient remained clinically stable, with slow bio-
chemical progression after transplantation. In July 2007, a
fifth line of treatment with thalidomide and cyclophos-
phamide was initiated. A partial response was achieved,
with grade 2 neurotoxicity, which lead to treatment inter-
ruption after eight cycles.
Four months later, progression was documented with
bone pain and an increase in bone marrow plasmacytosis. A
sixth line of treatment with lenalidomide and dexametha-
sone was introduced and a partial response was achieved.
This treatment continued until November 2010, when the
patient was admitted in the emergency room with paraple-
gia due to dorsal vertebra collapse and spinal cord compres-
sion. Emergency decompressive neurosurgery was
performed with complete neurological recovery. He then
initiated seventh treatment line with bortezomib, cyclo-
phosphamide, and dexamethasone, which was maintained
for 23 cycles and suspended in July 2012 due to grade 3 neu-
ropathy and frequent respiratory infections. The best
response achieved was stable disease. In January 2011 radio-
therapy was again necessary for bone pain control.
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Six months later, the patient started his eighth thera-
peutic line (idarrubicine and dexamethasone, interrupted
due to toxicities without response).
He was then started on pomalidomide and low-dose
dexamethasone. Repeated infectious and hematological
adverse events occurred, and the disease progressed after
four cycles. Currently, the patient has stable disease under
cyclophosphamide and dexamethasone.
Case 4
A 56 year-old woman patient with no relevant past clini-
cal history, was diagnosed with MM IgG kappa, Durie
Salmon stage IIB, ISS stage III in December 2001. At
diagnosis, the patient presented bone marrow plasmocy-
tosis of 68.4%, serum IgG of 1500 mg/dL, anemia and
renal insufficiency (Hb 9.2 g/dL, serum creatinine
1.6 mg/dL). At that time no cytogenetic abnormalities
were detected by FISH, but a del 13q14 was identified in
2002.
Right after diagnosis, treatment with VAMP for four
cycles was initiated. The patient developed renal failure
and hemodialysis was started. The treatment was altered
to cyclophosphamide and prednisolone, and kept for 12
cycles with the achievement of PR without renal function
recovery.
In July 2003 disease progression with bone pain and
increased serum IgG lead to a third line of treatment with
thalidomide and dexamethasone. The patient achieved
VGPR by the 18th cycle, with grade 2 neuropathy. In
November 2006, thrombosis of the hemodialysis fistula
occurred despite the thromboprophylaxis with aspirin.
The patient was kept on the same regimen until Octo-
ber 2008, when disease progression (painful bone lesions)
was observed. Radiotherapy, vertebroplasty, and treatment
with high-dose dexamethasone (fourth line) were started.
The patient completed 12 cycles in September 2009,
achieving VGPR.
She was kept on observation until January 2013, when
de novo lower back and right hip pain started. New bone
lesions and a soft tissue mass in the right femur were
documented without changes on bone marrow plasmocy-
tosis or biochemical progression. Local radiotherapy
improved the symptoms. At last follow-up, the disease is
stable without further treatment.
Discussion and Conclusion
The term “long-term survivor” in oncology refers
to patients alive for 10 or more years after the diagnosis
of cancer. In the case of MM, long-term survival is still
unusual and less than 10% of patients fulfill this criteria
[4, 7].
Nowadays, with expanded overall survival and a popu-
lation well aware of health information, myeloma patients
frequently discuss survival issues with their physicians
and it is important to note that both the overall and dis-
ease-free survival of those patients have been significantly
prolonged due to newer and more target-specific treat-
ments and adequate supportive care [4, 7, 24].
The cases presented here are good examples of long-term
MM control with different sequential treatment strategies.
While patient 3 clearly benefited from conventional chemo-
therapy (mainly melphalan), patients 1 and 2 were particu-
larly responsive to immunomodulation. All enjoyed
prolonged treatment-free intervals. Although we did not
identify specific biological or genetic characteristics in these
cases, they differ from the more commonly observed pattern
of progressively shorter remissions after multiple relapses.
Besides treatment options, prolongation of survival is,
in some cases (as illustrated in case 1), not simply related
to the use of novel drugs but possibly associated to clini-
cal prognostic factors and biological characteristics of the
disease. Cytogenetic and molecular characteristics of clo-
nal plasma cells are well-defined as prognostic factors
based on the results of several myeloma biology studies
and clinical trials [6, 11, 25, 26, 27, 28].
Although each patient had a different profile of
response all were long survivors. As such, there seems to
be, not one, but several profiles of long survivors in MM.
Case 1 exemplifies a highly chemo- and immunomodu-
lation-sensitive disease, as shown by good responses to all
treatment lines for the last 17 years. In this case, the pro-
longation of survival was evident even before the intro-
duction of new drugs. Notably the patient received only
three treatment lines and was never exposed to protea-
some inhibitors. This type of tumor allows treatment
strategies that may even exclude high-dose melphalan and
autologous transplantation, as suggested by the Mayo
Clinic treatment approach [29]. This case is also an
example of potential advantages for maintenance treat-
ment approaches that may prolong responses and, subse-
quently, overall survival.
Case 2 is a MM patient diagnosed 19 years ago. She
received mostly conventional chemotherapy regimens and
achieved mainly partial responses. With the introduction
of thalidomide, more prolonged disease control was pos-
sible at the cost of neurotoxicity that finally led to treat-
ment discontinuation. Currently this patient is under
lenalidomide and dexamethasone and achieved a new par-
tial response with significantly less toxicity. In this case, a
proteasome inhibitor was never used. The neurotoxicity
associated to the extensive use of thalidomide is now
known to preclude or delay treatment with bortezomib,
which must be taken in consideration when planning the
therapeutic approach to this chronic disease.
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Case 3 exemplifies the advantage of high-dose melpha-
lan and ASCT as a pathway to achieve better responses
and prolonged survival, even before the introduction of
novel drugs. This patient was diagnosed at an early age
and underwent three ASCT and several treatment lines
with a wide range of anti-MM drugs, including experi-
mental agents (pomalidomide). In this case, FISH studies
did not show any abnormality. However, the long clinical
course may have allowed an evolution through sequential
sensitive clones. More sensitive molecular methodologies
such as gene expression studies or DNA sequencing might
enlighten relevant genetic features explaining chemo-
sensitivity in similar clinical settings. This case is also an
example of the need for a multidisciplinary team to opti-
mize MM patient care, as well as of the importance of
maximizing the use of current drugs in order to allow
future access to drugs still under development.
Patient 4 illustrates the case of an early acute renal fail-
ure complicating a diagnosis of MM in a young woman,
who became dependent of dialysis regardless of what was
considered standard chemotherapy at that time. However,
even in this poor setting, deep and prolonged disease
control was possible. The patient received thalidomide,
corticosteroids, and local radiotherapy to control pain
related to isolated bone lesions. An improvement on renal
function was never achieved and neurological, thrombo-
embolic, and metabolic toxicities occurred over time,
which precluded the use of proteasome inhibitors. How-
ever, a reasonable quality of life is maintained and the
disease was controlled with few treatment lines and lim-
ited use of novel agents.
In addition to treatment options, long survival of mye-
loma patients might be related to biological characteristics
of tumor cells and/or microenvironment. Disease biology
is indeed one of the most important determinants of out-
come. Among patients with similar age, comorbidities,
and disease stage, survival can vary widely based on
genetic markers of aggressiveness [21, 30]. Although
scores based on cytogenetic abnormalities are used for
prognostic stratification, they not always directly dictate
treatments [9]. As such, detailed cytogenetic and molecu-
lar studies were not performed in the long-term survivors
presented here and cannot be used as an explanation for
the observed outcomes.
These observations underline the importance of other
variables interfering with overall survival, including com-
orbidities and fitness. These are typically approached in
the clinics by modifying treatment intensity and tailoring
therapeutic approaches. In this sense, hematologists tend
to avoid ASCT in patients with advanced age, and often
reduce the dose and intensity of chemotherapy to mini-
mize toxic side effects and maximize control of the dis-
ease. However, a recent study showed that ASCT is
feasible and well-tolerated in selected MM patients aged
>65. With the limitations of a retrospective case-match
analysis and differences in the treatments, novel agents
incorporated into ASCT seem to offer better outcomes in
comparison with novel agent-based treatments alone and
should be considered a valid option for fit elderly patients
[31]. On the other hand, the role of ASCT to treat fit and
young patients with MM was recently questioned as sev-
eral studies questioning the need for such an aggressive
approach are ongoing (studies from the European Mye-
loma Network and Italian group). Results from these
studies will help to clarify this question.
Better, patient-centered health care, aiming at specific
problems occurring in long survivors may minimize some
of the adverse events and increase quality of life. Multi-
disciplinary teams of health professionals including physi-
cians, psychologists, nutritionists, and physical therapists
may contribute to better evaluate the needs of long survi-
vors and design comprehensive survivor programs.
Besides therapeutic antimyeloma strategies aiming to con-
trol residual disease, these survivor programs may include
special attention to patient comorbidities, toxicity man-
agement, and physical, psychological, and social rehabili-
tation. Current approaches to cancer survivorship care
should include the integration of health care perspectives
with the needs of cancer survivors and the optimization
of practices in cancer survivorship care, overcoming
barriers for personalized approaches and exploring areas
for future research aimed at improving the quality of life
[32, 33].
The observed prolongation on MM patients’ survival
may allow statisticians to apply “cure models” as an alter-
native to the standard Cox proportional hazards models
to data showing prolonged survival trends [34, 35]. These
models may allow researchers to investigate what covari-
ates are associated with either short- or long-term effects.
The cases presented here are, however, good examples of
prolonged survival with reasonable controlled but persis-
tent disease. It is important to incorporate the concept of
quality of life in the management of these patients and
appreciate that long survivorship, even not leading to
cure, is very dependent on treatment strategies.
Currently, and given the prolongation of survival, we
may point three major controversies in MM management:
early versus late transplant, treatment or observation in
“high-risk” smoldering myeloma, and use of mainte-
nance/prolonged therapy. These controversies and the
answers hematologists may prefer are associated with the
perception of risks and benefits associated to each of the
choices. Although it is common thinking that patients
should receive upfront treatment with a triple or quadru-
ple combination of drugs, there is no absolute evidence
pointing to the need for combined therapies in the begin-
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ning of symptomatic disease; sequencing novel agents,
saving options for a later relapse, may be an alternative
and effective strategy in some cases. New phase III clinical
trials are needed to specifically address and clarify these
questions. Recently the concept of clonal evolution
through tides among the population of myeloma cells
showed the presence of several clones of tumor cells at
diagnosis, each with a different genetic makeup. The
results of that work also show that the dominant clone
changes over the course of the disease and is influenced
by treatments, with a given clone rising and falling over
time (known as clonal tides) [13]. These concepts provide
a rational basis for the definition of optimal sequential
treatment strategies for specific groups of MM patients,
maximizing the survival benefit through the appropriate
choice of drugs at different time-points. While the clinical
availability of such tools is limited to some centers, sur-
vival of MM patients depends not only on the availability
of multiple drug options but also on the personalized
decisions and multidisciplinary teams providing adequate
care during different stages of the disease, including (and
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